Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma

Conditions: Locally Advanced Esophageal Squamous Cell Carcinoma; Sintilimab; Radiotherapy; Concurrent Chemoradiotherapy; Immunonutrition Interventions: Radiation: Radiotherapy; Drug: Programmed Cell Death Protein 1 Inhibitor; Dietary Supplement: Immunonutrition support Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials